Toronto Dominion Bank’s Citius Pharmaceuticals CTXR Stock Holding History

Toronto Dominion Bank’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	–	–	1431
2022 Q1	$0	Hold	1	–	–	﹤0.01%	1526
2021 Q4	$0	Buy	+1	New	+$45	﹤0.01%	1591

Other funds holding CTXR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Toronto Dominion Bank's CTXR Position: Q2 2022 in Review

Toronto Dominion Bank sold out of Citius Pharmaceuticals (CTXR) in Q2 2022, closing a stake of 1 share.

Toronto Dominion Bank first reported a position in CTXR in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 60 funds tracked by Wall St. Rank hold CTXR as of Q2 2022.

Toronto Dominion Bank reported no remaining Citius Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Toronto Dominion Bank sold 1 Citius Pharmaceuticals share in Q2 2022.
Toronto Dominion Bank first reported a position in Citius Pharmaceuticals in Q4 2021 and held it in 2 quarters.
Toronto Dominion Bank's Citius Pharmaceuticals position peaked at $0 in Q1 2022.
60 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2022.

Based on Toronto Dominion Bank's 13F filing for Q2 2022, filed 11 Aug 2022.